Medtronic pays $380M-plus for Contego Medical buyout

Medtronic headquarters
The acquisition includes Contego's recently FDA-approved Neuroguard IEP Direct System. ()

Medtronic is boosting its cardiovascular disease portfolio with a deal to buy up carotid artery disease and peripheral thrombectomy tech company Contego Medical. 

Medtronic said the acquisition will build on its exclusive U.S. distribution agreement with Contego while boosting its strategy of pursuing targeted investments that strengthen its core franchises. 

This specifically expands the Medtronic portfolio of differentiated carotid technologies, broadening patient access to therapies for carotid artery and peripheral vascular disease.

The deal is worth $380 million with “potential payments post-acquisition,” Medtronic said in a Nov. 16 statement.

Medtronic’s Contego buy is in step with an active strategy of broadening its portfolio in 2026, and follows the acquisition of Cathworks, Scientia Vascular, and SPR Therapeutics.

"With this acquisition, Medtronic is taking another important step to strengthen our leadership in the treatment of carotid artery disease," said David Moeller, senior vice president and president of Medtronic Peripheral Vascular Health, in a release.

"By pairing Medtronic's deep clinical expertise in peripheral and neurovascular technologies with Contego's next-generation treatments backed by strong and consistent clinical data, we intend to become an undisputed leader in carotid revascularization."

Carotid artery disease occurs when the major blood vessels that send blood to the brain (carotid arteries) become narrowed or blocked. Plaque can rupture or embolize and lead to a stroke. While carotid revascularization is intended to reduce stroke risk, embolic debris released during treatment can contribute to procedural stroke risk. 

The buyout includes Contego's recently FDA-approved Neuroguard IEP Direct System, the first and only transcarotid artery revascularization system with integrated embolic protection (TCAR-IEP) in addition to flow reversal. 

Medtronic will also receive Contego's Excipio thrombectomy devices to complement Medtronic's Liberant thrombectomy system to treat peripheral vascular disease.